Workflow
Precision genetic medicine
icon
Search documents
Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript
Seeking Alpha· 2025-09-02 20:28
Question-and-Answer SessionSo let's just start with just an overview question, if we could, just introduce the company, the focus of the company, what are some of the key programs, and then we can get into detail on each of them.Alexander CumboPresident, CEO & Director Yes. Thank you, [indiscernible] for the invitation. Solid Biosciences is a precision genetic medicine company. We primarily focus right now on gene therapy. Three main drugs that are going to be either -- that are in the clinic, IND is open a ...
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
Globenewswire· 2025-07-22 12:00
SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on July 24, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi's CEO, Eric Poma, Ph.D. Attendees will gain insights into Calidi's pioneer ...
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
Globenewswire· 2025-05-28 12:00
Core Insights - Solid Biosciences Inc. is participating in the Jefferies Global Healthcare Conference on June 4, 2025, with a fireside chat featuring the President and CEO, Bo Cumbo, and Chief Medical Officer, Gabriel Brooks [1][2] Company Overview - Solid Biosciences is focused on developing precision genetic medicines targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, and catecholaminergic polymorphic ventricular tachycardia [3] - The company is advancing a diverse pipeline of gene therapy candidates and innovative libraries of genetic regulators aimed at improving gene therapy delivery across the industry [3] - Solid Biosciences was founded by individuals directly impacted by Duchenne, emphasizing its mission to enhance the daily lives of patients with rare diseases [3]
Solid Biosciences to Participate at The Citizens Life Sciences Conference
Globenewswire· 2025-04-30 12:00
Core Insights - Solid Biosciences Inc. is participating in The Citizens Life Sciences Conference on May 7, 2025, with CEO Bo Cumbo leading a fireside chat [1][2] Company Overview - Solid Biosciences is focused on developing precision genetic medicines targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, and catecholaminergic polymorphic ventricular tachycardia [3] - The company is advancing a diverse pipeline of gene therapy candidates and innovative technologies aimed at improving gene therapy delivery across the industry [3] - Solid Biosciences was founded by individuals directly impacted by Duchenne, emphasizing its mission to enhance the daily lives of patients with rare diseases [3]